Prophylactic Phenobarbital After Neonatal Seizures (PROPHENO)

This study has been terminated.
(Inadequate rate of enrollment)
Sponsor:
Information provided by (Responsible Party):
Ronnie Guillet, University of Rochester
ClinicalTrials.gov Identifier:
NCT01089504
First received: March 17, 2010
Last updated: June 8, 2012
Last verified: June 2012
  Purpose

The treatment of infants with medications after their seizures have stopped is very variable. No one knows if continuing treatment with phenobarbital for up to several months is helpful or harmful. This clinical trial is designed to help answer that question and provide data that will help determine standard of care for these children.


Condition Intervention Phase
Neonatal Seizures
Drug: phenobarbital
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Prophylactic Phenobarbital After Resolution of Neonatal Seizures

Resource links provided by NLM:


Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • Bayley Scales of Infant Development [ Time Frame: 18-22 months ] [ Designated as safety issue: No ]
    The Bayley Scales of Infant Development (BSID) measure the mental and motor development and test the behavior of infants from one to 42 months of age. The test is intended to measure a child's level of development in three domains: cognitive, motor, and behavioral. We propose to use mental development as the primary outcome for this trial.


Secondary Outcome Measures:
  • Bayley Scales of Infant Development - Motor [ Time Frame: 18-22 months ] [ Designated as safety issue: No ]
    This part of the BSID assesses the degree of body control, large muscle coordination, finer manipulatory skills of the hands and fingers, dynamic movement, postural imitation, and the ability to recognize objects by sense of touch.

  • Seizure recurrence [ Time Frame: 18-22 months ] [ Designated as safety issue: No ]
    Any clinical or electrographic seizures occurring between study entry and all follow-up examinations and contacts.


Enrollment: 13
Study Start Date: September 2010
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Phenobarbital
Phenobarbital, 4-5 mg/kg/day, for 4 months
Drug: phenobarbital
Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
Placebo Comparator: Placebo
Placebo in a volume equivalent to active drug for 4 months
Drug: placebo
Matched placebo, same volume as active drug, by mouth daily for 4 months

Detailed Description:

The treatment of infants with antiepileptic medications after the resolution of neonatal seizures is highly variable and controversial. Infants are commonly treated with phenobarbital after their seizures have resolved to prevent recurrence. Data to support this practice are lacking but animal models suggest that the neonatal brain is vulnerable to repeated seizures. Yet exposure of the developing brain to phenobarbital for prolonged periods may have deleterious consequences. We are proposing a multi-center, randomized, clinical trial (RCT) to determine if continued treatment with phenobarbital reduces seizure recurrence without adversely affecting neurodevelopmental outcome or if infants' outcomes are improved if no prophylactic medication is given. We will identify infants with seizures beginning in the first week that resolve within 7 days and randomize them to receive phenobarbital or placebo daily for four months. Via visits and frequent telephone contacts over the first six months, we will determine the rate of seizure recurrence. The primary outcome, neurodevelopmental status, will be assessed at 18-22 months using the Bayley Scales of Infant Development. Additional subgroup analyses are planned to determine the contribution of seizure etiology to outcome and predictive value of initial EEG classification. The trial will be conducted at 18 - 20 sites, chosen for their experience and proven track record for enrollment and retention in this specific population. The trial will be coordinated by the Clinical Trials Coordination Center at the University of Rochester and overseen by a Steering Committee composed of experienced trialists representing neonatology and pediatric neurology, biostatistics, and clinical trial administration.

Extrapolation from the results of an RCT of phenobarbital prophylaxis after febrile seizures in children suggests that phenobarbital may adversely affect brain development and may be ineffective in preventing seizures. Based on this previous RCT that resulted in near universal change in practice (the elimination of prolonged use of phenobarbital after simple febrile seizures), we anticipate that the data we generate may have a similar impact on standard of care for infants with neonatal seizures.

  Eligibility

Ages Eligible for Study:   up to 2 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Birth at > 34 weeks' gestation
  • Neonatal seizures (clinical, electrographic or both), with onset in the first 120 hours after birth and resolution within 7 days of onset
  • Parental informed consent

Exclusion Criteria:

  • Birth at < 34 weeks' gestation
  • If the attending neonatologist attributes the seizures solely to a transient abnormality, easily correctable and unlikely to recur (eg, transient electrolyte abnormalities). If the attending neonatologist cannot be contacted, the site PI will be asked to review the available information and judge whether the infant is eligible.
  • If the infant has been diagnosed with or there is a strong suspicion of an inborn error of metabolism, significant brain malformation, microcephaly (< 3 %ile), or a chromosomal abnormality which, in the absence of seizures, is known to be independently associated with an increased likelihood of cognitive impairment
  • If the infant has been diagnosed with an intrauterine viral infection
  • If the infant is not expected to survive to discharge
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01089504

Locations
United States, Arkansas
University of Arkansas
Little Rock, Arkansas, United States, 72202
United States, California
University of California San Francisco
San Francisco, California, United States, 94143
United States, Iowa
Univeristy of Iowa
Iowa City, Iowa, United States, 52242
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21224
United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, New York
Women & Children's Hospital of Buffalo
Buffalo, New York, United States, 14222
University of Rochester
Rochester, New York, United States, 14642
United States, North Carolina
Wake Forest University
Winston Salem, North Carolina, United States, 27157
Forsyth Medical Center
Winston Salem, North Carolina, United States, 27157
United States, Ohio
Akron Children's Hospital
Akron, Ohio, United States, 44308
Nationwide Children's Hospital
Columbus, Ohio, United States, 43205
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15224
Magee Womens Hospital
Pittsburgh, Pennsylvania, United States, 15224
United States, Rhode Island
Women & Infants Hospital of Rhode Island
Providence, Rhode Island, United States, 02905
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84108
Primary Children's Medical Center
Salt Lake City, Utah, United States, 84108
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
University of Rochester
Investigators
Principal Investigator: Ronnie Guillet, MD, PhD University of Rochester
  More Information

No publications provided

Responsible Party: Ronnie Guillet, Professor, University of Rochester
ClinicalTrials.gov Identifier: NCT01089504     History of Changes
Other Study ID Numbers: 28907
Study First Received: March 17, 2010
Last Updated: June 8, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Rochester:
phenobarbital
neonate
antiepileptic drugs
neurodevelopmental outcome
seizure

Additional relevant MeSH terms:
Seizures
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Phenobarbital
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
GABA Modulators
GABA Agents

ClinicalTrials.gov processed this record on August 27, 2014